Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 168

1.

Stable remission and recovery after acute-phase cognitive therapy for recurrent major depressive disorder.

Vittengl JR, Clark LA, Thase ME, Jarrett RB.

J Consult Clin Psychol. 2014 Dec;82(6):1049-59. doi: 10.1037/a0037401. Epub 2014 Jul 21.

2.

Predictors of longitudinal outcomes after unstable response to acute-phase cognitive therapy for major depressive disorder.

Vittengl JR, Clark LA, Thase ME, Jarrett RB.

Psychotherapy (Chic). 2015 Jun;52(2):268-77. doi: 10.1037/pst0000021.

3.

Longitudinal social-interpersonal functioning among higher-risk responders to acute-phase cognitive therapy for recurrent major depressive disorder.

Vittengl JR, Clark LA, Thase ME, Jarrett RB.

J Affect Disord. 2016 Jul 15;199:148-56. doi: 10.1016/j.jad.2016.04.017. Epub 2016 Apr 13.

5.

Effects of adding cognitive therapy to fluoxetine dose increase on risk of relapse and residual depressive symptoms in continuation treatment of major depressive disorder.

Perlis RH, Nierenberg AA, Alpert JE, Pava J, Matthews JD, Buchin J, Sickinger AH, Fava M.

J Clin Psychopharmacol. 2002 Oct;22(5):474-80.

PMID:
12352270
6.

Quantifying and qualifying the preventive effects of acute-phase cognitive therapy: Pathways to personalizing care.

Jarrett RB, Minhajuddin A, Vittengl JR, Clark LA, Thase ME.

J Consult Clin Psychol. 2016 Apr;84(4):365-76. doi: 10.1037/ccp0000069. Epub 2015 Dec 14.

7.

Improved cognitive content endures for 2 years among unstable responders to acute-phase cognitive therapy for recurrent major depressive disorder.

Vittengl JR, Clark LA, Thase ME, Jarrett RB.

Psychol Med. 2015 Nov;45(15):3191-204. doi: 10.1017/S0033291715001191. Epub 2015 Jun 22.

8.

Preventing depressive relapse and recurrence in higher-risk cognitive therapy responders: a randomized trial of continuation phase cognitive therapy, fluoxetine, or matched pill placebo.

Jarrett RB, Minhajuddin A, Gershenfeld H, Friedman ES, Thase ME.

JAMA Psychiatry. 2013 Nov;70(11):1152-60. doi: 10.1001/jamapsychiatry.2013.1969.

9.

Initial Steps to inform selection of continuation cognitive therapy or fluoxetine for higher risk responders to cognitive therapy for recurrent major depressive disorder.

Vittengl JR, Anna Clark L, Thase ME, Jarrett RB.

Psychiatry Res. 2017 Jul;253:174-181. doi: 10.1016/j.psychres.2017.03.032. Epub 2017 Mar 22.

PMID:
28388454
10.

Deterioration in psychosocial functioning predicts relapse/recurrence after cognitive therapy for depression.

Vittengl JR, Clark LA, Jarrett RB.

J Affect Disord. 2009 Jan;112(1-3):135-43. doi: 10.1016/j.jad.2008.04.004. Epub 2008 Jun 9.

11.

Continuation-phase cognitive therapy's effects on remission and recovery from depression.

Vittengl JR, Clark LA, Jarrett RB.

J Consult Clin Psychol. 2009 Apr;77(2):367-71. doi: 10.1037/a0015238.

12.

Defined symptom-change trajectories during acute-phase cognitive therapy for depression predict better longitudinal outcomes.

Vittengl JR, Clark LA, Thase ME, Jarrett RB.

Behav Res Ther. 2016 Dec;87:48-57. doi: 10.1016/j.brat.2016.08.008. Epub 2016 Aug 18.

13.

Moderators of continuation phase cognitive therapy's effects on relapse, recurrence, remission, and recovery from depression.

Vittengl JR, Clark LA, Jarrett RB.

Behav Res Ther. 2010 Jun;48(6):449-58. doi: 10.1016/j.brat.2010.01.006. Epub 2010 Feb 4.

14.

How much cognitive therapy, for which patients, will prevent depressive relapse?

Jarrett RB, Vittengl JR, Clark LA.

J Affect Disord. 2008 Dec;111(2-3):185-92. doi: 10.1016/j.jad.2008.02.011. Epub 2008 Mar 21.

15.

Cognitive reactivity, dysfunctional attitudes, and depressive relapse and recurrence in cognitive therapy responders.

Jarrett RB, Minhajuddin A, Borman PD, Dunlap L, Segal ZV, Kidner CL, Friedman ES, Thase ME.

Behav Res Ther. 2012 May;50(5):280-6. doi: 10.1016/j.brat.2012.01.008. Epub 2012 Feb 21.

16.

Continued Effectiveness of Relapse Prevention Cognitive-Behavioral Therapy Following Fluoxetine Treatment in Youth With Major Depressive Disorder.

Emslie GJ, Kennard BD, Mayes TL, Nakonezny PA, Moore J, Jones JM, Foxwell AA, King J.

J Am Acad Child Adolesc Psychiatry. 2015 Dec;54(12):991-8. doi: 10.1016/j.jaac.2015.09.014. Epub 2015 Oct 8.

PMID:
26598474
17.

Preventing recurrent depression using cognitive therapy with and without a continuation phase: a randomized clinical trial.

Jarrett RB, Kraft D, Doyle J, Foster BM, Eaves GG, Silver PC.

Arch Gen Psychiatry. 2001 Apr;58(4):381-8.

18.

Improvement in self-reported quality of life with cognitive therapy for recurrent major depressive disorder.

Jha MK, Minhajuddin A, Thase ME, Jarrett RB.

J Affect Disord. 2014;167:37-43. doi: 10.1016/j.jad.2014.05.038. Epub 2014 Jun 2.

19.

Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report.

Nierenberg AA, Husain MM, Trivedi MH, Fava M, Warden D, Wisniewski SR, Miyahara S, Rush AJ.

Psychol Med. 2010 Jan;40(1):41-50. doi: 10.1017/S0033291709006011. Epub 2009 May 22.

PMID:
19460188
20.

Influence of sex and menopausal status on response, remission, and recurrence in patients with recurrent major depressive disorder treated with venlafaxine extended release or fluoxetine: analysis of data from the PREVENT study.

Kornstein SG, Pedersen RD, Holland PJ, Nemeroff CB, Rothschild AJ, Thase ME, Trivedi MH, Ninan PT, Keller MB.

J Clin Psychiatry. 2014 Jan;75(1):62-8. doi: 10.4088/JCP.12m07841.

PMID:
24345717

Supplemental Content

Support Center